Abstract
Introduction
Treatment of terminal patients aims to improve the quality of life of patients with lifelimiting conditions by emphasizing relief from pain and symptoms, by involving their family and friends, and by adopting a holistic, non-curative focus. However, health care systems have a limited ability to meet the needs of terminal patients and to keep a balance between costs and quality of care at the end of life. In addition to the effectiveness of care models for terminal patients, policy makers and health care payers are concerned about the costs of treating terminal patients in a context of spiralling health care costs and limited resources. evidence on the cost drivers of treating terminal patients. For instance, a Belgian retrospective analysis found that hospitalisation during the three final months of life was less likely if, amongst other things, the general practitioner provided palliative care and if treatment had a palliative rather than a curative focus (3) .
The aim of this article is to review the international literature on the costs of treating terminal patients. The literature review was undertaken as part of a larger study on palliative care in Belgium commissioned by the Belgian Healthcare Knowledge Centre. The article focuses on the level, distribution and drivers of costs of treating terminal patients, and appraises the methodological quality of cost studies. The cost estimates and methodological perspective provided by this article may serve to determine priorities for and inform future research on terminal patients, and may be used in future economic evaluations exploring the cost-effectiveness of various care models for terminal patients.
Methods

Search strategy
Studies were identified by searching PubMed, Centre for Reviews and Dissemination 
Inclusion/exclusion criteria
The literature review targeted studies on the costs of treating terminal patients. Inclusion was limited to studies that contrasted costs in different healthcare settings, and to studies that compared palliative care with alternative therapeutic approaches for terminal patients. Studies that analyzed costs at end of life in general, but did not focus specifically on terminal patients were excluded. Our review did not incorporate economic evaluations investigating the cost-effectiveness of various therapeutic approaches for terminal patients. Another exclusion criterion was studies that failed to convert health care resource utilization into costs.
Inclusion was restricted to articles published in peer-reviewed journals. Congress abstracts were not considered because they do not provide sufficient details of methodology and results.
7.
Data analysis
To compare costs between studies, costs were actualized to 2007 values using a rate of inflation based on the evolution of the Consumer Price Index. Costs were converted using purchasing power parities for Belgium, i.e. market exchange rates adjusted for differences in purchasing power between countries and Belgium.
It was not appropriate to synthesise cost estimates of treating terminal patients across studies due to the heterogeneity of the primary studies. This heterogeneity derives from the fact that the health care setting; type of hospital and hospital unit; nature and content of palliative care and usual care; time horizon of cost assessment; cost measures; and study design varied between cost studies. There was insufficient common ground for pooling cost estimates that would permit quantitative summarization and, hence, results are presented for each cost study separately.
Assessment of methodological quality
A qualitative appraisal was carried out of the methodological quality of cost studies. An appraisal form was filled in by the lead author for each study focusing on study sample, data sources, methods of data collection, scope of included costs and time horizon (4) .
With respect to the sample, studies can be based on a representative national sample or enroll a specific group of patients. Data can be collected prospectively / retrospectively from patient medical records, a survey, a claims database or the literature. Cost studies 8.
can be designed as a case series following up terminal patients, a case-control study comparing terminal patients with control patients, or a cohort study contrasting treatment approaches or health care settings for terminal patients. Studies can measure direct health care costs (e.g. medicines, surgical procedures, visits to health care providers, hospitalization), direct non-health care costs (e.g. transportation to the health care provider), and indirect costs arising from productivity loss. Estimates can be presented as charges based on official list prices or costs based on actual resource use. Finally, the time horizon was identified over which costs of treating terminal patients were measured.
Results
Few studies have investigated the costs of treating terminal patients: the researchers identified 56 papers, for which the abstract was assessed. Based on the abstract, nine papers were excluded because they either measured costs at the end of life rather than costs of terminal patients, they quantified health care resource utilization but did not convert it into costs, or they carried out an economic evaluation rather than a cost study.
The full manuscript of the remaining 47 articles was assessed. Of these articles, 32 articles were excluded for the same reasons as stated previously, and 15 articles were included in the review (see Figure 1 ). 
Costs of treating terminal patients across health care settings
Costs of treating terminal patients in hospital
A case series measured and identified the determinants of palliative care costs of hepatocellular carcinoma in Hong Kong (7). Two hundred and four patients were enrolled. The analysis was undertaken from a societal perspective, including costs of formal and informal services incurred by payers, caregivers and patients. The mean cost for formal health services per patient amounted to 3,546 € from first hospitalisation until death. A regression analysis showed that severity and chemotherapy increased formal 11. service costs per day, but patient age, number of days of observation and survivorship decreased formal service costs per day. This study did not include a control group of patients and results were specific to patients suffering from inoperable hepatocellular carcinoma.
A prospective cohort study calculated costs of palliative care in two hospitals providing general medicine, surgical and obstetric care and in two hospitals offering extended care and rehabilitation in France (8) . Predictive factors of palliative care costs were identified.
The analysis enrolled 119 patients. Total costs per day amounted to 493 € for all patients, 547 € for patients admitted to hospitals providing general medicine, and 440 € for patients admitted to hospitals providing extended care. The cost difference between the two types of hospital was explained by the fact that palliative care units in hospitals providing general medicine employed more staff. Total costs consisted of staff salaries (62% of costs), logistical expenses (23%), overheads (5%), medicines (5%), depreciation of heavy equipment (3%), disposable devices (1%), and diagnostic tests (1%). The following variables were predictive of higher costs: degree of anxiety of patients and their family; proximity of death; extreme dependence; ear, nose and throat cancer; young patient age; and the provision of certain procedures. Although this study was carried out in a limited number of palliative care units and enrolled a small number of patients, the authors concluded that the population of patients in palliative care units is not homogeneous from an economic point of view. In other words, palliative care unit costs depend on patient characteristics.
12.
A US case-control study included 38 patients admitted to a hospital palliative care unit and 38 patients who died outside the palliative care unit and who were cared for by other medical or surgical teams (9) . The palliative care unit was a dedicated 11-bed inpatient unit staffed by a high-volume specialist team using standardised care. The analysis collected data on charges (based on official list prices) and on costs (based on actual resource use). The palliative care unit generated lower daily charges (-59%) and lower daily costs (-57%). Some of these savings originated from discontinuing costly interventions once patients were clearly identified as dying. It was not clear to what extent the high volume of the palliative care unit produced economies of scale and lowered costs.
A cohort study calculated costs of patients admitted to a hospital palliative care unit as compared to patients admitted to an intensive care unit or any unit other than palliative care in the United States (10). In addition to this, approaches to controlling costs of a palliative care unit were identified. The cost per day for hospitalised patients during the last 20 days leading to their death was significantly lower on the palliative care unit than on intensive care units and non-palliative care units. As a consequence, the authors emphasised the importance of admitting patients to the palliative care unit at the right time with a view to containing costs. Approaches to controlling costs included: a) appropriate admissions to the palliative care unit; b) direct admissions from the emergency department to the palliative care unit; and c) transfer of patients from more costly sites of care (e.g. intensive care unit) to the palliative care unit. Finally, palliative 13 . 
14.
A similar US study investigated costs of patients who received an inpatient palliative care consultation with costs of inpatients who received usual care (13) . However, this study enrolled a larger sample of patients (4,908 palliative care patients and 20,551 usual care patients), matched control patients to cases, included patients from eight diverse hospitals, and measured costs rather than charges. Also, this study distinguished between patients who were discharged alive and patients who died. Hospital costs related to costs of the intensive care unit, pharmacy, laboratory, and diagnostic imaging tests. Palliative 
Costs of treating terminal patients at home
The costs of palliative care at home were computed in an Italian case series (14) . The home care service provided a telephone hotline to patients and the team consisted of oncologists and nurses with additional skills in cancer nursing. This service was restricted to patients with an estimated life span of two months or less as estimated by clinicians.
Costs of the home care service amounted to 39.9 € per patient per day. This figure   15 . Higher costs of the terminal phase and of the curable phase could be attributed to the higher number of medical and nursing visits, and transfusions required by such patients.
This study showed that home care costs depend on disease status of patients. However, other variables that may influence home care costs, such as age and diagnosis of patients, were not controlled for. Also, the number of patients included in some disease status groups was relatively small.
16.
A retrospective, observational study enrolled all patients undergoing palliative care who died from cancer in a Spanish town in 1998 (16) . Patients received either standard care management (111 patients) or home care support by a specialised team (44 patients). The perspective was that of the Catalan Health Service and the time horizon was one month.
Mean costs per patient were lower for patients receiving home support than for patients receiving standard care management (-683 €). This cost advantage of home support originated from lower costs of hospitalisation, outpatient care use, emergency department visits, and days of stay in palliative care units in nursing homes. However, the authors could not rule out selection bias as possible differences in characteristics between patient groups (e.g. illness severity) may influence cost estimates. Cost estimates also reflected the practices of one specialised home support team and may not be applicable to other
teams.
An Israeli analysis compared health care costs of two models of delivering palliative care at home to terminally-ill patients during their last year of life (17) . Costs of 120 patients receiving home-specialised palliative care services were contrasted with those of 515 patients receiving home non-specialised palliative care services. No detailed description of home (non-)specialised palliative care services was provided by the authors. Health care costs of home-specialised services were 30% lower than those of non-specialised services during the last year of life. The cost difference increased nearer the time of death. Lower costs of home-specialised services could be attributed to lower costs of hospitalisations and of oncology treatments. The authors argued that this may be 17.
explained by the nature of the specialised palliative care approach which provides for around the clock support and routine visits to patients by staff.
The cost impact of two new services allowing patients to be cared for at home was explored by a retrospective before-and-after study in England (18) increasing to 146 € if unpaid resources (e.g. volunteers) were included. The authors also found that patients who attend palliative day care access a different package of care than those who do not. This may reflect differences in characteristics of these two groups of patients and imply that palliative day care and palliative home care are not substitutes.
Discussion
The body of evidence on the costs of treating terminal patients was small and varied.
Although palliative care requires a multidimensional and interdisciplinary approach, few studies calculated palliative care costs across health care settings. These studies showed that hospitalisation costs represent the principal component of palliative care costs. A number of studies focused on palliative care in hospitals. The results consistently indicated that palliative care is cheaper than usual care or care delivered in hospital units other than the palliative care unit. Therefore, our analysis supports the policy recommendation that hospitals need to pay attention to admitting patients to the palliative care unit at the right time from a cost perspective. Also, there is some evidence pointing to cost advantages of palliative care at home as compared to alternative care models, although this needs to be corroborated by further research. If palliative care is viewed as a component of a broader care programme (e.g. a comprehensive oncology programme), no study has examined the cost impact of palliative care on the care programme.
Cost studies vary in terms of how a terminal patient is defined. This variety in definitions is also observed in the epidemiological and clinical literature. Based on a literature 19.
review, different approaches have been proposed to define the 'terminal' status: a) by the patient 'readiness' i.e. the patient is ready to address terminal issues when he/she is aware of his/her prognosis; b) by the severity of illness: 'Is this patient sick enough that it would not be a surprise if he or she would die within 6 months (or 3 or 12 months)?'; and c) by the prognosis expressed by the physician as the risk of dying at a time in the future (20) .
Other authors have identified terminal patients by adding the content of care given: when curative or life-prolonging treatments are decided not to be pursued (21) . Given the observed variety of definitions, our analysis did not propose a definition of a 'terminal patient' as a criterion to include/exclude cost studies, but summarized the available studies on terminal patients, recognizing that they used different definitions. This variety in definitions implies that inclusion/exclusion criteria and, hence, cost estimates differ between studies.
The reader must be careful when comparing costs of treating terminal patients between studies for a number of reasons (22) . First, the organisation and financing of health care systems vary between countries, implying that therapeutic services, their availability and associated costs differ. Second, as stated above, the definition of a terminal patient differs between studies. Third, the definition, nature and content of palliative care and usual care vary between studies. Fourth, studies generally did not consider patient out of pocket expenses, which vary between countries. Caution needs to be exercised when comparing the costs of different approaches to delivering palliative care to terminal patients. This is because the results of the literature 20.
review indicate that palliative care costs depend on patient characteristics such as diagnosis, status of disease and age. The population of patients receiving palliative care is heterogeneous from a cost perspective. Also, different care models appear to target different patient groups and offer varied packages of services. This implies that different approaches to delivering palliative care are not substitutes of each other.
The literature on the costs of treating terminal patients suffers from a number of methodological shortcomings. In the absence of randomised controlled trials, selection bias where patients self-select into a specific care model is an issue that is likely to influence cost estimates. Some sample sizes were too limited to draw generalisable conclusions. A combination of survey and claims data was used in studies to obtain information about the costs of treating terminal patients. The reliability of survey data is hindered by patients' ability to recall health resource utilization and costs. Claims data may suffer from missing data and incorrect coding of claims. Studies enrolling a specific group of patients tend to be carried out prospectively using survey data. This type of analysis can be considered to be more reliable than studies based on a retrospective analysis of claims databases. Cost estimates were derived for specific patient samples and are unlikely to be applicable to the population of terminal patients.
Studies need to move away from using charge data based on official list prices towards measuring costs based on actual resource use. This is because, for instance, charges for treating terminal patients in hospital may not accurately reflect actual expenditure on administration, billing, capital depreciation, maintenance, laundry and other hospital 21.
services. Alternatively, in studies that measure charges, these need to be converted into costs by means of cost-to-charge ratios. Such adjustment by cost-to-charge ratios is regularly used in cost studies set in the United States (4).
The scope of included costs was generally restricted to direct health care costs associated with treating terminal patients. This refers to costs of medicines, contacts with health care professionals and hospitalization. Table 2 identifies the major cost items that need to be considered when calculating the costs of treating terminal patients from a societal perspective. In addition to direct health care costs, studies need to focus on eliciting direct non-health care costs associated with transportation to the health care professional and indirect costs arising from lost productivity. With respect to the latter, attention needs to be paid to calculating the indirect costs of reduced ability to attend school, work or carry out usual daily activities.
There was substantial variation between studies in how an episode of care was defined and in the time horizon over which costs were measured. The majority of studies quantified costs over a fixed time period prior to death or from the start of a specific health care service (e.g. hospitalization) until the time of death. In practice, this meant that the time horizon could range from 20 days to two years. Other studies focused on a specific hospitalization episode. Ideally, costs need to be computed from the time of diagnosis of a terminal patient until the time of death.
22.
Future studies need to set up a prospective collection of primary data on healthcare resource use and costs of treating terminal patients. This type of analysis can be considered to be more reliable than retrospective analyses of patient medical records or claims databases. Alternatively, modeling approaches can be considered that are based on high-quality data, closely reflect real-life practice and the evolution of terminal patients, and test the robustness of cost estimates through extensive sensitivity analyses.
23. The palliative unit generated lower daily charges (-59%) and lower daily costs (-57%). 
28. 
